Marcus Buschbeck, researcher at the Institute of Predictive and Personalized Medicine of Cancer (IMPPC) of Badalona has explained its latest advances in the investigation of a protein involved in DNA packaging and its involvement in cell differentiation in the October 21 cycle IDIBELL seminars. The aim of Buschbeck group is to understand how cell changes […]
Most malignant cells die; only survive those who adapt better Certain healthy liver cells promote an adaptive response in colorectal cancer cells by inhibiting proliferation and causing their death. Tumor cells, that adapt themselves to new conditions, change their behavior and morphology, favoring migration. Researchers from the IDIBELL and the Catalan Institute of Oncology (ICO), coordinated by David Garcia Molleví have published the results of this study in the journal Neoplasia . A hostile microenvironment Article’s reference
The Catalan Institute of Oncology has been awarded by the Catalan business association CECOT in the ‘Reconeixements 2011’ awards Good Practices
CECOT rewards ICO’s management Read More »
University Hospital of Bellvitge has been awarded for the third consecutive year and fifth time during its history (2004, 2006, 2009, 2010 and 2011), as one of the best hospitals in Spain.
Researchers from IDIBELL have collaborated on a study characterizes a protein called RBM38, key in the regulation of tumor cell death, which is disabled in breast tumors, making them more resistant to some chemotherapy treatments. Practical application Article’s reference
IDIBELL hosted DREAM, RECOMB and RICCI conferences on October 14 -19th On October 14 -19 IDIBELL has hosted the 6th Annual DREAM on Reverse Engineering Challenges, the 7th Annual RECOMB Satellite on Systems Biology and the 8th Annual RECOMB on Regulatory Genomics , which were first held outside the U.S.
Bioinformatics, systems biology and functional genomics, protagonists at IDIBELL Read More »
The University Hospital of Bellvitge and IDIBELL coordinate the clinical trial which included over 500 patients
A multicenter trial will allow marketing a genetic test for endometrial cancer Read More »
IDIBELL researchers and professionals of the Psychiatry Service of the Bellvitge University Hospital have been awarded the prize for best European serious game on health category for the therapeutic videogame: Playmancer. The award will be presented in the course of the Fun & Serious Game Festivalthat will take place on 8 and 9 November in
Playmancer project, awarded as the best European serious game on health Read More »
Most malignant cells die; only survive those who adapt better Certain healthy liver cells promote an adaptive response in colorectal cancer cells by inhibiting proliferation and causing their death. Tumor cells, that adapt themselves to new conditions, change their behavior and morphology, favoring migration. Researchers from the IDIBELL and the Catalan Institute of Oncology (ICO), coordinated by David Garcia Molleví have published the results of this study in the journal Neoplasia . A hostile microenvironment Article’s reference
Cedars-Sinai Medical Center (Los Angeles) and IDIBELL have signed an agreement of cooperation on technology transfer. The agreement suppose the mutual support to increase technology transfer activities as well as access to the U.S. market for the commercialization of products or technologies developed by IDIBELL.
IDIBELL and Cedars-Sinai join efforts for technology transfer Read More »
